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tions, reﬂecting differences in early time points and in illness
severity levels. For schizophrenia patients with at least moderate
symptom severity, the lack of at least 14–23% improvement on
the PANSS total score at two weeks is an optimal predictor of
subsequent non-response following eight weeks of treatment.
This early response threshold appears to be an important clinical
marker of subsequent non-response to antipsychotic therapy.
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OBJECTIVE: To evaluate the 12-month clinical and functional
outcomes in patients with schizophrenia who received RLAI
treatment and were enrolled in the electronic-Schizophrenia
Treatment Adherence Registry (e-STAR) in Australia and
Belgium, and the Schizophrenia Outcomes Utilization, Relapse,
and Clinical Evaluation (SOURCE) in the United States.
METHODS: e-Star and SOURCE are long-term, prospective,
observational studies of patients with schizophrenia who com-
mence RLAI treatment. Data are collected both retrospectively
and prospectively and clinical effectiveness was measured by the
Clinical Global Impression Severity (CGI-S) scale and patient
functioning was measured by the Global Assessment of Function-
ing (GAF) scale. RESULTS: Seven hundred sixty-nine patients
(Australia = 493, Belgium = 163, USA = 113) with 12-months
of follow-up data were included. Australia had signiﬁcantly
younger patients than Belgium and the United States (mean ages:
Australia = 38.6, Belgium = 41.6, USA = 43.5; p = 0.0003). Time
since diagnosis (in years) was signiﬁcantly higher in the United
States than Australia and Belgium (USA = 17.6, Australia = 11.6,
Belgium = 9.8; p < 0.0001). United Stats patients had signiﬁ-
cantly higher baseline GAF scores than the Australian and
Belgian patients (USA = 50.9, Australia = 42.7, Belgium = 43.1;
p < 0.0001). Despite baseline differences, GAF and CGI-S scores
at 12-months for patients treated with RLAI signiﬁcantly
improved from baseline in all three countries. CGI-S scores sig-
niﬁcantly decreased by 0.8 (p < 0.001), 1.08 (p < 0.001) and
0.83 (p < 0.001) points and GAF scores signiﬁcantly increased by
12.7 (p < 0.001), 14.8 (p < 0.001), and 11.1 (p < 0.001) points in
Australia, Belgium, and the United States respectively. CON-
CLUSION: This interim analysis from the two observational
studies shows that despite differences in patient characteristics
among countries, treatment with RLAI resulted in signiﬁcant
improvements in disease severity and patient functioning in
patients with schizophrenia from all three countries.
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OBJECTIVE: To assess differences in treatment duration and
resource utilization following initiation on atypical antipsychot-
ics among schizophrenia patients with versus without metabolic
syndrome who were treated at the Veteran Health Administra-
tion. METHODS: We used electronic medical records data for
October 2002-August 2005 from a large Veterans Integrated
Service Network (VISN16) to identify schizophrenia patients
who were initiated on an atypical antipsychotic and have under-
gone metabolic monitoring in the 180 days prior to medication
initiation. Those found to have a metabolic syndrome (MetSyn+)
were compared to those without (MetSyn-) on patient charac-
teristics, treatment duration, medication adherence per medica-
tion possession ratio (MPR), and resource utilization in the
1-year post medication initiation. Kaplan-Meyer (K-M) estima-
tion compared the difference in treatment duration. A Cox pro-
portional hazard regression was used to compare all-cause
medication discontinuation, controlling for group differences at
baseline. RESULTS: A minority of schizophrenia patients who
have undergone metabolic monitoring was found to have a meta-
bolic syndrome (83 of 593, or 14.0%). The MetSyn+ and
MetSyn- groups did not signiﬁcantly differ on baseline charac-
teristics except that the MetSyn+ group had a higher rate of
non-VA insurance. Adherence (MPR) during the year following
medication initiation was higher for the MetSyn+ group (81% vs.
68%; p = 0.031). K-M estimators (log-rank test p = 0.471; Wil-
coxon test p = 0.512) and a Cox model (p = 0.671) indicated
lack of statistically signiﬁcant group difference in all-cause medi-
cation discontinuation. CONCLUSION: Among schizophrenia
patients who have undergone metabolic monitoring, those with a
metabolic syndrome and those without do not appear to differ on
treatment duration and resource utilization following initiation
on an atypical antipsychotic medication in the Veterans Health
Administration.
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OBJECTIVE: Continuous treatment is an important goal in the
management of schizophrenia. Retention rate is a well-recognized
global measure of effectiveness that integrates patients’ and clini-
cians’ judgment of efﬁcacy, safety and tolerability. Furthermore,
all-cause discontinuation was used as a primary outcomemeasure
in a large effectiveness study (Clinical Antipsychotic trial of Inter-
vention Effectiveness or CATIE). The current study utilized lon-
gitudinal claims data fromOntario Drug Beneﬁt (ODB) recipients
in Ontario, Canada to compare retention rates for typical and
atypical antipsychotic medications with different formulations.
METHODS: Longitudinal data were obtained for ODB recipients
that were initiated on antipsychotic therapy in July 2006. ODB
recipients were followed from their ﬁrst claim for the speciﬁc
target drug to their last claim in a 12-month period. Rates of
retention were determined throughout and up until 12 months.
Descriptive analyses were performed. Retention rates were
reported for depot (long-acting injectable) risperidone; oral atypi-
cal antipsychotics including olanzapine, risperidone, and quetiap-
ine; orally disintegrating tablet formulations of risperidone and
olanzapine; oral typical antipsychotics (pooled); and depot typical
antipsychotics (pooled). RESULTS: From July 2006–June 2007,
12-month retention rates were lowest with oral typical (29% of
recipients), depot typical antipsychotics (30%), and risperidone
orally disintegrating formulations (30%). Retention rates for oral
atypical antipsychotics were 41% for olanzapine, 46% for risperi-
done and 50% for quetiapine. Retention on risperidone long-
acting injectable were the highest with 73% of recipients retained
over 12-months. CONCLUSION: Retention rates were lowest
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